URGN Description — UroGen Pharma Ltd
UroGen Pharma is a biotechnology company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co. has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Co.'s Jelmyto® (mitomycin) for pyelocalyceal solution, and its UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively.
|
|
Free URGN Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.60 out of 4) 62nd percentile
(ranked higher than approx. 62% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|